Long-term cognitive deficits induced by a single, extremely low dose of tetrahydrocannabinol (THC): Behavioral, pharmacological and biochemical studies in mice

Pharmacology Biochemistry and Behavior

Volumn 88, Issue 3, 2008, Pages 230-237

  Senn, Roey ^a   Keren, Ora ^a   Hefetz, Aya ^a   Sarne, Yosef ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

9 tetrahydrocannabinol (THC); Cannabinoid; CB1 receptor; Cognitive deficits; Extracellular signal regulated kinase (ERK); SR141716A; Water T maze

Indexed keywords

CANNABINOID 1 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RIMONABANT; TETRAHYDROCANNABINOL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL ANALYSIS; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVATION; LOW DRUG DOSE; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SINGLE DRUG DOSE;

ANIMALS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; BRAIN CHEMISTRY; COGNITION DISORDERS; ENZYME INDUCTION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HALLUCINOGENS; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; PIPERIDINES; PSYCHOMOTOR PERFORMANCE; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL;

CANNABIS SATIVA; MUS;

EID: 36148983440     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2007.08.005     Document Type: Article

References (61)

1. Adams I.B., and Martin B.R. Cannabis: pharmacology and toxicology in animals and humans. Addiction 91 (1996) 1585-1614
2. Agell N., Bachs O., Rocamora N., and Villalonga P. Modulation of the Ras/Raf/MEK/ERK pathway by Ca(2+), and calmodulin. Cell Signal 14 (2002) 649-654
3. Agurell S., Halldin M., Lindgren J.E., Ohlsson A., Widman M., Gillespie H., et al. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38 (1986) 21-43
4. Baker D., Pryce G., Giovannoni G., and Thompson A.J. The therapeutic potential of cannabis. Lancet Neurol 2 (2003) 291-298
5. Block R.I. Does heavy marijuana use impair human cognition and brain function?. Jama 275 (1996) 560-561
6. Bouaboula M., Poinot-Chazel C., Bourrie B., Canat X., Calandra B., Rinaldi-Carmona M., et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312 Pt 2 (1995) 637-641
7. Derkinderen P., Valjent E., Toutant M., Corvol J.C., Enslen H., Ledent C., et al. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci 23 (2003) 2371-2382
8. Di Marzo V., Bifulco M., and De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev. Drug Discov 3 (2004) 771-784
9. Ehrenreich H., Rinn T., Kunert H.J., Moeller M.R., Poser W., Schilling L., et al. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berl) 142 (1999) 295-301
10. Federico F., Leggio M.G., Neri P., Mandolesi L., and Petrosini L. NMDA receptor activity in learning spatial procedural strategies II. The influence of cerebellar lesions. Brain Res Bull 70 (2006) 356-367
11. Fehr K.A., Kalant H., and LeBlanc A.E. Residual learning deficit after heavy exposure to cannabis or alcohol in rats. Science 192 (1976) 1249-1251
12. Fried P.A., Watkinson B., and Gray R. Neurocognitive consequences of marihuana-a comparison with pre-drug performance. Neurotoxicol Teratol 27 (2005) 231-239
13. Galve-Roperh I., Rueda D., Gomez del Pulgar T., Velasco G., and Guzman M. Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. Mol Pharmacol 62 (2002) 1385-1392
14. Grant I., Gonzalez R., Carey C.L., Natarajan L., and Wolfson T. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc 9 (2003) 679-689
15. Grant I., Rochford J., Fleming T., and Stunkard A. A neuropsychological assessment of the effects of moderate marihuana use. J of Nerv Ment Dis 156 (1973) 278-280
16. Guzman M., Sanchez C., and Galve-Roperh I. Cannabinoids and cell fate. Pharmacol Ther 95 (2002) 175-184
17. Guzman M., Sanchez C., and Galve-Roperh I. Control of the cell survival/death decision by cannabinoids. J Mol Med 78 (2001) 613-625
18. Hampson A.J., Grimaldi M., Axelrod J., and Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 95 (1998) 8268-8273
19. Hill M.N., Patel S., Carrier E.J., Rademacher D.J., Ormerod B.K., Hillard C.J., et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 30 (2005) 508-515
20. Jager G., Kahn R.S., Van Den Brink W., Van Ree J.M., and Ramsey N.F. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacology 185 (2006) 358-368
21. Kanayama G., Rogowska J., Pope H.G., Gruber S.A., and Yurgelun-Todd D.A. Spatial working memory in heavy cannabis users: a functional magnetic resonance imaging study. Psychopharmacology 176 (2004) 239-247
22. Landfield P.W., Cadwallader L.B., and Vinsant S. Quantitative changes in hippocampal structure following long-term exposure to delta 9-tetrahydrocannabinol: possible mediation by glucocorticoid systems. Brain Res 443 (1988) 47-62
23. Lawston J., Borella A., Robinson J.K., and Whitaker-Azmitia P.M. Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55,212-2. Brain Res 877 (2000) 407-410
24. Liou A.K., Clark R.S., Henshall D.C., Yin X.M., and Chen J. To die or not to die for neurons in ischemia, traumatic brain injury and epilepsy: a review on the stress-activated signaling pathways and apoptotic pathways. Prog Neurobiol 69 (2003) 103-142
25. Lyketsos C.G., Garrett E., Liang K.Y., and Anthony J.C. Cannabis use and cognitive decline in persons under 65 years of age. Am J Epidemiol 149 (1999) 794-800
26. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302 (2003) 84-88
27. Marsicano G., Moosmann B., Hermann H., Lutz B., and Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 80 (2002) 448-456
28. Mauler F., Hinz V., Augstein K.H., Fassbender M., and Horvath E. Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271. Brain Res 989 (2003) 99-111
29. Mechoulam R., Panikashvili D., and Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 8 (2002) 58-61
30. Mechoulam R., Spatz M., and Shohami E. Endocannabinoids and neuroprotection. Sci STKE 2002 (2002) RE5
31. Mereu G., Fa M., Ferraro L., Cagiano R., Antonelli T., Tattoli M., et al. Prenatal exposure to a cannabinoid agonist produces memory deficits linked to dysfunction in hippocampal long-term potentiation and glutamate release. Proc Natl Acad Sci U S A 100 (2003) 4915-4920
32. Morris R.G., Garrud P., Rawlins J.N., and O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 297 (1982) 681-683
33. Murray B., Alessandrini A., Cole A.J., Yee A.G., and Furshpan E.J. Inhibition of the p44/42 MAP kinase pathway protects hippocampal neurons in a cell-culture model of seizure activity. Proc Natl Acad Sci U S A 95 (1998) 11975-11980
34. Nagayama T., Sinor A.D., Simon R.P., Chen J., Graham S.H., Jin K., et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19 (1999) 2987-2995
35. O'Shea M., McGregor I.S., and Mallet P.E. Repeated cannabinoid exposure during perinatal, adolescent or early adult ages produces similar longlasting deficits in object recognition and reduced social interaction in rats. J Psychopharmacol 20 (2006) 611-621
36. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Perchuk A., Meozzi P.A., et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 1074 (2006) 514-536
37. Panikashvili D., Simeonidou C., Ben-Shabat S., Hanus L., Breuer A., Mechoulam R., et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413 (2001) 527-531
38. Peinado-Manzano M.A. The role of the amygdala and the hippocampus in working memory for spatial and non-spatial information. Behav Brain Res 38 (1990) 117-134
39. Petrosini L., Molinari M., and Dell'Anna M.E. Cerebellar contribution to spatial event processing: Morris water maze and T-maze. Eur J Neurosci 8 (1996) 1882-1896
40. Pope Jr. H.G., and Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. Jama 275 (1996) 521-527
41. Rubino T., Forlani G., Vigano D., Zippel R., and Parolaro D. Modulation of extracellular signal-regulated kinases cascade by chronic delta 9-tetrahydrocannabinol treatment. Mol Cell Neurosci 25 (2004) 355-362
42. Rubovitch V., Gafni M., and Sarne Y. The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells. Brain Res Mol Brain Res 101 (2002) 93-102
43. Rubovitch V., Gafni M., and Sarne Y. The involvement of VEGF receptors and MAPK in the cannabinoid potentiation of Ca2+ flux into N18TG2 neuroblastoma cells. Brain Res. Mol Brain Res 120 (2004) 138-144
44. Runden E., Seglen P.O., Haug F.M., Ottersen O.P., Wieloch T., Shamloo M., et al. Regional selective neuronal degeneration after protein phosphatase inhibition in hippocampal slice cultures: evidence for a MAP kinase-dependent mechanism. J Neurosci 18 (1998) 7296-7305
45. Sanchez C., Galve-Roperh I., Rueda D., and Guzman M. Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol Pharmacol 54 (1998) 834-843
46. Sarne Y., and Keren O. Are cannabinoid drugs neurotoxic or neuroprotective?. Med Hypotheses 63 (2004) 187-192
47. Sarne Y., and Mechoulam R. Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets-Cns Neurol Disord 4 (2005) 677-684
48. Scallet A.C. Neurotoxicology of cannabis and THC: a review of chronic exposure studies in animals. Pharmacol Biochem Behav 40 (1991) 671-676
49. Scallet A.C., Uemura E., Andrews A., Ali S.F., McMillan D.E., Paule M.G., et al. Morphometric studies of the rat hippocampus following chronic delta-9-tetrahydrocannabinol (THC). Brain Res 436 (1987) 193-198
50. Skaper S.D., Buriani A., Dal Toso R., Petrelli L., Romanello S., Facci L., and Leon A. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci U S A 93 (1996) 3984-3989
51. Solowij N., Michie P.T., and Fox A.M. Differential impairments of selective attention due to frequency and duration of cannabis use. Biol Psychiatry 37 (1995) 731-739
52. Solowij N., Stephens R.S., Roffman R.A., Babor T., Kadden R., Miller M., et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. Jama 287 (2002) 1123-1131
53. Stanciu M., Wang Y., Kentor R., Burke N., Watkins S., Kress G., et al. Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J Biol Chem 275 (2000) 12200-12206
54. Stiglick A., and Kalant H. Behavioral effects of prolonged administration of delta 9-tetrahydrocannabinol in the rat. Psychopharmacology (Berl) 80 (1983) 325-330
55. Stiglick A., and Kalant H. Learning impairment in the radial-arm maze following prolonged cannabis treatment in rats. Psychopharmacology (Berl) 77 (1982) 117-123
56. Stiglick A., and Kalant H. Residual effects of prolonged cannabis administration on exploration and DRL performance in rats. Psychopharmacology (Berl) 77 (1982) 124-128
57. Tonini R., Ciardo S., Cerovic M., Rubino T., Parolaro D., Mazzanti M., et al. ERK-dependent modulation of cerebellar synaptic plasticity after chronic Delta9-tetrahydrocannabinol exposure. J Neurosci 26 (2006) 5810-5818
58. Tselnicker I., Keren O., Hefetz A., Pick C.G., and Sarne Y. A single low dose of tetrahydrocannabinol induces long-term cognitive deficits. Neurosci Lett 411 (2007) 108-111
59. van der Stelt M., Veldhuis W.B., Bar P.R., Veldink G.A., Vliegenthart J.F., and Nicolay K. Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 21 (2001) 6475-6479
60. van der Stelt M., Veldhuis W.B., van Haaften G.W., Fezza F., Bisogno T., Bar P.R., et al. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neurosci 21 (2001) 8765-8771
61. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (2005) 329-332